Skip to content

Pharmacovigilance services

Pharmacovigilance, or drug safety, is crucial to understanding a drug, biologic or combination product’s risk-benefit profile and protecting the welfare of patients by systematically detecting and assessing adverse events. 

Pharmacovigilance servicestwo-women-notes

We offer pharmacovigilance services including SUSAR reporting, medical monitoring, and coding of adverse events, medical history and prior/concomitant medications.

Monitoring drug safety

Pharmacovigilance is the study of detecting, assessing, and understanding adverse effects to monitor the safety of medicines. Drug safety monitoring is performed during clinical studies and we can support you with medical monitoring, SAE reporting, and SUSAR reporting to the regulatory authorities. In addition, pharmacovigilance is an important part of the product’s entire lifecycle and we also support sponsors with routine safety reporting to the authorities (DSURs/PSURs).

Medical monitors work closely with the sponsor and sites to perform qualified medical reviews of, for example, SAEs/SUSARs as well as providing general oversight and immediate support when safety issues arise. We understand that when it comes to safety, what we do is as important as how we do it, and in addition to regulatory compliance, we believe that clear communication, efficient reporting procedures, and seamless collaboration are essential for success.

Pharmacovigilance services also include:

  • Safety reporting including SUSARs, DSURs/PSURs, and patient safety narratives
  • Medical monitoring including medical review of clinical data and consultation with medical monitors
  • Coding of adverse events, medical history and prior/concomitant medications

Contact us for more information

Meeri Säily
Meeri Säily
Sales Director

Leave a contact request

Latest news

Meet us at SPML in Porto!

We will be at the SPML's (Sociedade Portuguesa de Medicina Laboratorial) 17th scientific meeting on 3-5 April 2025 in...

Aurevia appoints Jonna Pelanti as the new Head of EQA business area

We are delighted to announce the appointment of the new Head of the EQA business area Jonna Pelanti.
Meet us at BioMedica in Dublin on 18-20 March.

Meet us at BioMedica in Dublin

Meet us at the BioMedica exhibition at booth A18!

Aurevia appoints Ulrika Hammarström as the new Head of CRO business area

We are delighted to announce the appointment of the new Head of the CRO business area Ulrika Hammarström.
EQA pilot studies in 2025

Introducing the EQA Pilot Studies 2025

Register now for this year's EQA pilot studies! They will be conducted starting in March.